Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

GPC Biotech, Yakult in satraplatin pact
July 2007
SHARING OPTIONS:

MUNICH, Germany—GPC Biotech AG  recently announced that it entered into a license agreement with Yakult Honsha Co. Ltd. for satraplatin in Japan. Under the terms of the agreement, Yakult gains exclusive commercialization rights to satraplatin for Japan and will take the lead in developing the drug in Japan. Yakult is to provide an upfront payment of 1.2 billion yen (about $10 million) to GPC Biotech as reimbursement for past satraplatin clinical development expenses. Yakult will also make GPC Biotech additional payments based on the achievement of certain regulatory filing and approval milestones. GPC Biotech will also receive a minimum of 21 percent royalties on sales of satraplatin in Japan.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.